Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CNR2 | P34972 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | KCNK3 | O14649 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 0.91 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.91 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anandamide SCHEMBL13100719 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1CNR2MEN1BLM | |
| Anandamide SCHEMBL43143 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1CNR2MEN1BLM | |
| Anandamide SCHEMBL43144 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1CNR2MEN1BLM | |
| Anandamide SCHEMBL4109856 | 1.00 | CNR1 (1.00) | CNR1ALDH1A1CNR2MEN1BLM | |
| SCHEMBL15364953 | 0.98 | CNR1 (0.97) | CNR1ALDH1A1CNR2MEN1BLM | |
| SCHEMBL29512269 | 0.98 | CNR1 (0.97) | CNR1ALDH1A1CNR2MEN1BLM | |
| Anandamide SCHEMBL27412236 | 0.98 | CNR1 (0.97) | CNR1ALDH1A1CNR2MEN1BLM | |
| SCHEMBL4539275 | 0.98 | CNR1 (0.97) | CNR1ALDH1A1CNR2MEN1BLM | |
| SCHEMBL14700549 | 0.98 | CNR1 (0.97) | CNR1ALDH1A1CNR2MEN1BLM | |
| SCHEMBL14864037 | 0.98 | CNR1 (0.97) | CNR1ALDH1A1CNR2MEN1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200170962-A1 | NASAL CANNABIDIOL COMPOSITIONS | LEWEKE F MARKUS (AU) | 2020-06-04 | — | — | US | disclosed |
| US-6509367-B1 | Pyrazole cannabinoid agonist and antagonists | VIRGINIA COMMONWEALTH UNIVERSITY | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200170962-A1 | NASAL CANNABIDIOL COMPOSITIONS | CNR2, CNR1, FAAH | CNR1 2/4885ALDH1A1 4339/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.